Business
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization\nHOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The cost-of-care analysis suggests that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precision, and reduced hospitalizations. The findings support the potential clinical and economic value of CNSide as the Company advances commercialization of the assay in the United States. The data will be presented at the ISPOR 2026 Annual Meeting, the leading global scientific conference focused on health economics and outcomes research (HEOR), bringing together researchers, healthcare decision-makers, and payer stakeholders. The meeting will take place May 17-20, 2026, in Philadelphia, PA. “CNSide’s ability to detect and monitor tumor cells in cerebrospinal fluid provides clinicians with actionable information earlier in the disease course,” said Russ Havranek, EVP, Commercial and Corporate Strategy of Plus Therapeutics. “Health economics data demonstrating potential cost savings and improved outcomes are increasingly important to payers and health systems evaluating adoption of advanced diagnostics.” Presentation HighlightsThe poster, titled, “Economic Impact of Earlier Detection and Therapeutic Management of Leptomeningeal Metastases Using CNSide: A Cost-of-Care Analysis,” co-authored by CNSide Diagnostics and Harvard T.H. Chan School of Public Health, will highlight the following: Late-stage LM diagnosis is associated with substantial healthcare costs, including median inpatient admissions of ~$20,000 (Interquartile range (IQR) $10,000-$30,000)Total LM-related costs may exceed $100,000 per month, driven by repeated imaging, LM-directed therapies, and...